- Home
- NUW vs SLS Comparison
NUW vs SLS Comparison
Compare NUW & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUW | SLS |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.0M | 706.7M |
| IPO Year | 2008 | 2007 |
Fundamental Metrics
Financial Performance| Metric | NUW | SLS |
|---|---|---|
| Price | $14.30 | $5.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 28.3K | ★ 5.7M |
| Earning Date | 01-01-0001 | 04-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.69 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.04 | $0.95 |
| 52 Week High | $14.62 | $6.14 |
Technical Indicators
Market Signals| Indicator | NUW | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 40.52 | 62.68 |
| Support Level | $14.29 | $1.48 |
| Resistance Level | $14.40 | N/A |
| Average True Range (ATR) | 0.10 | 0.51 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 12.50 | 70.51 |
Price Performance
Historical ComparisonAbout NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. The Fund's primary investment objective is to provide current income exempt from regular federal income tax. The Fund's secondary investment objective is to enhance portfolio value and total return.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.